Mobilizing the Immune System in the Treatment of Alzheimer’s Disease
TARGETING THE ANTIGEN-PRESENTING CELLS OF THE IMMUNE SYSTEM TO ENHANCE IMMUNITY AND TRANSPORT ANTI-INFLAMMATORY AND ANTIPROLIFERATIVE AGENTS TO DISEASE SITES
The Antigen-presenting Cells (APCs) are responsible for maintaining the immune system’s balanced and measured response to disease by producing a broad array of signals to mobilize cellular, cytokine, and antibody defenses. Specialized APCs, the circulating monocytes, migrate to disease sites where they are transformed into pro-inflammatory or anti-inflammatory macrophages. While both types of macrophage play vital roles in defense against diseases, excessive production of either type is counter therapeutic. Elevated ratios of pro-inflammatory macrophages contribute to neuroinflammatory diseases such as Alzheimer’s, while elevated ratios of anti-inflammatory macrophages contribute to tumor growth, metastasis, and progression of cancers.
TARGETING THE APCS WITH THE CLR-TARGOSPHERE®
Augustus Bio Target has secured a platform targeting technology, the TargoSphere®, from Rodos Bio Target GmbH in Germany in a collaborative agreement designed to develop novel treatments for neurodegenerative diseases and cancers. The CLR-TargoSphere® is a patented carbohydrate-labeled nanocarrier that recognizes carbohydrate receptor sites on the surface of APCs and delivers encapsulated agents into a pathway that evades intracellular endolysosomal enzymatic degradation. The ability to escape degradation is critical to the successful delivery of unmodified and pharmacologically active agents to diseased sites, and is unique among all competing targeted and non-targeted nanocarriers.
Additionally, the CLR-TargoSphere® has been shown to deliver therapeutic contents across the Blood Brain Barrier, concentrated in perivascular spaces and areas rich in glial cells, with intracellular delivery into astrocytes, the cells intimately associated with Alzheimer’s disease and demyelinating disorders such as Multiple Sclerosis.
- CLR-TargoSphere® encapsulated paclitaxel
- CLR-TargoSphere® encapsulated curcumin
- CLR-TargoSphere® encapsulated gemcitabine
Paclitaxel: a generic apoptotic, antiproliferative, and immune-enhancing agent. In addition to its approved use for multiple oncologic indications, it also inhibits abnormal protein tau hyperphosphorylation in Alzheimer’s disease.
Curcumin: a generic natural curcuminoid antiproliferative and anti-inflammatory agent. It also has anti-amyloidogenic activity and induces degradation of amyloid beta deposits and uptake by macrophages in Alzheimer’s disease.
Gemcitabine: a generic antiproliferative agent approved for multiple oncologic indications, has synergistic antiproliferative activities with paclitaxel and curcumin. A non-targeted combination of gemcitabine and paclitaxel (nab-paclitaxel) was FDA approved in 2013 as a first-line treatment for metastatic pancreatic carcinoma. The CLR-TargoSphere® targeted combination of gemcitabine, paclitaxel, and curcumin is designed to improve clinical outcomes over non-targeted gemcitabine and nab-paclitaxel.
OUR CLINICAL GOALS:
CLR-TargoSphere® encapsulated gemcitabine, paclitaxel, and curcumin have been developed for in-vivo preclinical and clinical trials to:
- ALZHEIMER’S DISEASE: Administer the CLR-TargoSphere® encapsulated combination of paclitaxel and curcumin to cross the Blood Brain Barrier for a dual treatment strategy to retard development of tau neurofibrillary tangles and impaired synaptic transmission, and to decrease formation and aggregation of amyloid deposits.The Goal: Delay progression of cognitive impairments in early and mid-stage Alzheimer’s disease.
- METASTATIC PANCREATIC ADENOCARCINOMA: Administer the CLR-TargoSphere® encapsulated combination of gemcitabine, paclitaxel, and curcumin to the primary tumor, metastases, and tumor-draining lymph nodes for a synergistic antiproliferative.The Goal: Improve progression-free and overall survival rates in comparison to the combination of non-targeted gemcitabine and nab-paclitaxel.
In the News…
Drug Development in Alzheimer’s Disease: the Path to 2025
The global impact of Alzheimer’s disease (AD) continues to increase, and focused efforts are needed to address this immense public health challenge. National leaders have set a goal to prevent or effectively treat AD by 2025. Read more…
We are developing an Immunotherapeutic Approach to the Treatment of Early and Mid-Stage Alzheimer Dementias
Invest in EquityNet Crowdfunding to Help Develop Our New Alzheimer Treatment:
For more information visit the Alzheimer’s Disease Project page.
Rodos Biotarget will host ‘Future Medicine Symposium’
Augustus BioTarget is using a specialized Rodos nanocarrier to target the immune system in the development of a new treatment for Alzheimer’s disease. Read more…
NANOSCALE TARGETING – Lab Times, March 2016
Early summer 2012, when Robert Furch was facing his young company’s doom, was a truly awful time. With venture capital running out and no investor in sight things looked bad. Most start up entrepreneurs can sympathise with this nightmare. But in the end, the situation wasn’t as bad as it seemed. Furch and his colleagues on the board dug deep into their own pockets to bridge the finance gap for a few months. Good decision! Before the summer of 2012 ended, by 1 August in fact, they had secured a comforting, external follow-up financing. Since then, their drug delivery company, Rodos Biotarget, has been back on track.
Download and read the rest (PDF): Lab Times – Nanoscale Targeting – March 2016
To develop innovative treatment options for neurodegenerative and demyelinating diseases, and cancers by targeting antiproliferative and anti-inflammatory agents to communicating cells of the immune system.